TLSA · Tiziana Life Sciences Ltd. Common Shares
View on chartInsiders & Stakes
| Gabriele M. Cerrone Director | ▲ Buy | Grant | 44,814,587 Shares held | 7/21/2026 | View profile |
| Ivor Elrifi Chief Executive Officer | ▲ Buy | Option Exercise | 5,843,684 Shares held | 8/15/2026 | View profile |
Transaction History
| Ivor Elrifi | ▲ Buy | Option Exercise | 1,050,000 | — | 8/15/2026 |
| Ivor Elrifi | ▲ Buy | Open Market | 237,616 | $238K | 8/5/2026 |
| Ivor Elrifi | ▲ Buy | Open Market | 83,807 | $81K | 8/4/2026 |
| Ivor Elrifi | ▲ Buy | Open Market | 667,000 | $667K | 8/3/2026 |
| Gabriele M. Cerrone | ▲ Buy | Grant | 42,357 | $42K | 7/21/2026 |
| Gabriele M. Cerrone | ▲ Buy | Grant | 15,000 | $17K | 6/12/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TLSA Doses First ALS Patients, Completes MS Trial Visits
Tiziana Life Sciences has started dosing patients in its intranasal foralumab ALS trial, with the first three participants receiving the first dose. The company also completed patient visits in its Phase 2a multiple sclerosis trials, including the INFORM‑MS study, and the last patient finished the final visit. Topline results from the MS trial are expected in October, which will give insight into the drug’s safety and effectiveness.
TLSA Doses First ALS Patients, Completes MS Trial Visits. Tiziana Life Sciences has started dosing patients in its intranasal foralumab ALS trial, with the first three participants receiving the first dose. The company also completed patient visits in its Phase 2a multiple sclerosis trials, including the INFORM‑MS study, and the last patient finished the final visit. Topline results from the MS trial are expected in October, which will give insight into the drug’s safety and effectiveness.